|Renal Diseases Drug Development Pipeline Review: 2018 - Therapeutics Under Development and Key Players Involved - ResearchAndMarkets.com|
|Friday, 11 January 2019 00:06|
Jan. 11, 2019 10:48 UTC
Renal Diseases Drug Development Pipeline Review: 2018 - Therapeutics Under Development and Key Players Involved - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)-- The "Renal Diseases Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.
Renal Diseases Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for renal diseases.
It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.
Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.
1 Table of Contents
3 Therapeutics Development
4 Therapeutics Assessment
5 Companies Involved in Therapeutics Development
6 Dormant Projects
7 Discontinued Products
8 Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/jh93df/renal_diseases?w=4
Source: Research and Markets